The GLP-1 Graveyard Is Getting Crowded

That's three pharmaceutical giants with deep pockets and massive manufacturing capacity, all fighting over the same patients. For a UK-based biotech that licensed its pipeline from China's Sciwind Biosciences, the math starts looking grim.

The competitive bar has shifted from "can you make an oral GLP-1 that works?" to "can you make one that works better than what three of the world's largest drugmakers are already selling or about to sell?" That's a very different question.

Verdiva Isn't the Only One Running for the Exits

What makes this story bigger than one cancelled trial is the pattern. Verdiva's pullback is part of a 2025-2026 wave of obesity program cancellations that reads like a casualty list.

Pfizer killed its oral GLP-1 candidate danuglipron after a potential liver injury signal, having already scrapped an earlier oral effort called lotiglipron. Terns Pharmaceuticals shelved TERN-601 after disappointing Phase 2 results and liver concerns. Zealand Pharma suspended its obesity drug dapiglutide to focus elsewhere. Even Novo Nordisk, the undisputed king of GLP-1, dropped multiple pipeline assets, including a GLP-1/GIP combination program.

Roche cut obesity assets it had acquired through its Carmot deal. Amgen scrapped an early-stage weight loss molecule called AMG 786. Lilly terminated a mid-stage trial of a muscle-sparing obesity combination. The reasons cluster into three buckets: safety problems, weak efficacy, or the strategic realization that being the fifth-best oral GLP-1 isn't a business model.

This isn't companies giving up on obesity. It's companies giving up on undifferentiated obesity programs. The difference matters.

What Verdiva Is Betting On Instead

Verdiva isn't folding entirely. It's reshuffling the deck. The company's core bet remains VRB-101, which it describes as a cAMP-biased GLP-1 peptide analog (translation: a GLP-1 drug designed to activate the receptor in a slightly different, potentially better way). The drug uses a proprietary delivery technology and is dosed once weekly, which could be an edge over daily oral competitors.

The EVOLVE-2 trial, which completed enrollment earlier in 2026, is still on track. If the data looks good, Verdiva has talked about moving into Phase 3 in 2027.

Perhaps more interesting is VRB-103, an oral amylin analog in Phase 1 testing. Amylin is a different hormone that also suppresses appetite, and Verdiva's plan is to eventually combine it with VRB-101. Think of it like a cocktail approach: instead of turning up one appetite dial, you turn up two.

This combination strategy is exactly the kind of differentiation the market is rewarding right now. Being "another oral GLP-1" is a death sentence for small biotechs. Being "an oral GLP-1 plus oral amylin, both once-weekly" is a much more interesting pitch to investors and, eventually, to doctors.

The Bigger Picture

The obesity drug market is still projected to grow aggressively through the mid-2030s, so this isn't an "obesity is over" story. It's a natural selection story. The companies that survive will be the ones with best-in-class data, genuine differentiation, or the financial muscle to outlast the competition.

For investors watching the obesity biotech space, the signal is clear: valuation gaps are going to widen. Companies with unique mechanisms, strong late-stage data, or clever combination strategies will pull further ahead. The "me-too" oral GLP-1 plays will keep getting trimmed.

Verdiva's trial will be a footnote. But the question it raises isn't small at all: in a market dominated by giants, how small is too small to compete? Verdiva is betting it can still win with the right cards. The EVOLVE-2 readout, expected by year's end, will tell us whether that's confidence or wishful thinking.

Novartis Just Bet $7.8 Billion That Your Body Can Build Its Own Medicine

Novartis just paid $575 million upfront for access to Abogen's RNA technology, in a deal worth up to $7.8 billion. The bet: that your own cells can be programmed to build medicines from scratch, starting with a clever new approach to autoimmune disease.